Does Rallies show 13F holders for OPRX?

Yes. Rallies tracks hedge fund and 13F ownership data for OPRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is OPRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OPRX. It does not provide personalized investment advice.

OPRX (OptimizeRx Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

OptimizeRx Corporation Common Stock (OPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, OPRX trades at $5.24 with a market cap of $95.51M and a P/E ratio of 17.54. OPRX moved +3.00% today. Year to date, OPRX is -62.26%; over the trailing twelve months it is -58.41%. Its 52-week range spans $3.78 to $22.25. Analyst consensus is strong buy with an average price target of $12.00. Rallies surfaces OPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns OPRX stock?

Hedge funds tracked by Rallies that own OPRX include Centerbook Partners and Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for OptimizeRx Corporation Common Stock.

OPRX Key Metrics

Key financial metrics for OPRX
Metric	Value
Price	$5.24
Market Cap	$95.51M
P/E Ratio	17.54
EPS	$0.28
Dividend Yield	0.00%
52-Week High	$22.25
52-Week Low	$3.78
Volume	1.06K
Avg Volume	0
Revenue (TTM)	$109.43M
Net Income	$5.13M
Gross Margin	67.25%

Top Hedge Funds Holding OPRX

Centerbook Partners holds 25.22K shares of OPRX, changed -91.83% as of Dec 31, 2025.
Panagora Asset holds 12.71K shares of OPRX, changed +0.00% as of Sep 30, 2025.

Latest OPRX News

OptimizeRx Taps DSPs for Programmatic EHR Ads, Targets $19B Pharma Market — May 13, 2026
OptimizeRx Posts Double-Digit AI Engagement Growth, Revenue Slips in Q1 — May 13, 2026
OptimizeRx Narrows Q1 Loss and Raises 2026 Revenue Guidance to $95-$100M — May 12, 2026
OptimizeRx Enables DSPs to Tap 90% U.S. Digital Display Ad Spend — May 11, 2026
OptimizeRx Appoints Microsoft Health COO Mary Varghese Presti to Drive Subscription Revenue — Apr 8, 2026

Recent OPRX Insider Trades

Stelmakh Edward sold 1.39K (~$18.75K) on Dec 19, 2025.
Silvestro Stephen L sold 1.62K (~$30.38K) on Oct 3, 2025.
Spangler Patrick D sold 11.12K (~$194.49K) on Aug 28, 2025.

OPRX Analyst Consensus

6 analysts cover OPRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.00.

Common questions about OPRX

Who owns OPRX stock?: Hedge funds tracked by Rallies that own OPRX include Centerbook Partners and Panagora Asset. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for OptimizeRx Corporation Common Stock.
Does Rallies show 13F holders for OPRX?: Yes. Rallies tracks hedge fund and 13F ownership data for OPRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is OPRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OPRX. It does not provide personalized investment advice.